The Pharma Rotation Resets Itself Overnight

The Breadth Picture Has Not Cleared

On 2026-03-11, $20.18$ of the US equity universe printed new 20-day lows. New 20-day highs reached only $5.04$. The ratio is approximately $4:1$ in favor of deterioration — fractionally improved from the $4.7:1$ recorded on March 10, but not in a direction that constitutes a regime change. Breadth above the 50-day moving average sits at $34.05$, down $1.31$ percentage points from the prior session. Breadth is not recovering. It is compressing further.

Risk pressure eased from $19.19$ to $15.13$ — a decline of $4.06$ percentage points. That is the one number in today's dataset that points toward potential stabilization. The vol shock ratio is $3.53$ and the volume surge ratio is $7.19$, both lower than March 10's readings of $3.91$ and $9.72$ respectively. The acute stress of the prior session has moderated. The structural deterioration has not.

These readings describe a market still under distribution. The easing in risk pressure is not a reversal signal; it is a reduction in velocity. The broad tape remains in a risk-off configuration.

What the Signal Filter Changed Overnight

Of $4{,}550$ symbols scanned, $3{,}879$ passed quality filters and $2{,}218$ triggered at least one technical signal. The signal architecture on the sell side remains consistent with March 10: momentum_20_negative_cross ($218$ triggers), ichimoku_cloud_breakdown ($204$), rsi_centerline_bear ($194$), and bollinger_lower_breakdown ($123$). The sell-side signals are not abating. They are restating the same deterioration across a slightly smaller universe.

What changed is the composition of the bullish signals. On March 10, oscillator-based signals — williams_r_buy at $1{,}072$, stochastic_buy at $918$ — dominated the buy side numerically but reflected oversold conditions rather than genuine momentum shifts. On March 11, CCI buy leads with $534$ triggers, followed by Williams %R buy at $243$, stochastic buy at $145$, and Ichimoku breakout at $142$. The total buy-signal count has compressed. Fewer names are triggering buy signals, but the Ichimoku breakout count — a structurally stronger signal than an oversold oscillator — is now prominent.

The signal architecture is becoming more selective.

A Completely New Pharma/Biotech Cohort

The top-ranked bullish names from March 10 — Dyne Therapeutics (DYN), United Therapeutics (UTHR), Xenon Pharmaceuticals (XENE) — do not appear in today's trade plan. All three have been removed in the overnight rebalance. In their place, an entirely new cohort of pharma and biotech names occupies the top of the composite signal ranking.

NIO (the China EV manufacturer) leads the universe scan with a composite decision score of $100$ and six simultaneous buy signals: MACD golden cross, Ichimoku breakout, price above the 200-day moving average, Bollinger upper breakout, Keltner breakout, and positive momentum cross. Six independent technical frameworks confirming simultaneously is the same structural pattern that DDD produced on March 10. NIO is a categorically different business — an operationally stressed Chinese EV maker with significant capital requirements — but the technical architecture is unambiguous.

Tenax Therapeutics (TENX) and BridgeBio Pharma (BBIO) each score $100$ with six and five buy signals respectively. Vertex Pharmaceuticals (VRTX) scores $100$ with five buy signals. ATRenew (RERE), a China-based refurbished electronics ADR, scores $100$. Amarin (AMRN) and MeiraGTx (MGTX) score $99$. BIOA, MAZE, and ZNTL — all early-stage biotech names — score $99$ each.

This is not the same pharma rotation that was present on March 10. The March 10 cohort featured established, cash-generative healthcare businesses — UTHR generates roughly $2$ billion in annual operating cash flow; REGN is a large-cap immunology franchise. The March 11 cohort is weighted toward smaller, more speculative biotech names alongside a China EV ADR and two China-adjacent names. The sector theme persists — pharma and biotech — but the risk profile within that sector has shifted meaningfully toward the speculative end of the spectrum.

Micron Technology (MU) appears at a composite of $92$ with four buy signals, providing the one large-cap semiconductor name with a technically constructive setup. Honeywell (HON) scores $88$ — an industrial with a durable earnings profile, appearing in the bullish cohort for the first time in this scan sequence.

The Bond ETFs Are Gone

On March 10, four investment-grade bond ETFs — USIG, VCLT, ISTB, and VTC — appeared in the top tier of the signal scan, scoring between $92$ and $95$. Their presence in the trade plan at $3.4$ allocation each was the most explicit statement in the data of a flight-to-quality rotation. The signal was unambiguous: capital was moving from equities into investment-grade fixed income.

On March 11, none of those bond ETFs appear in the trade plan. All four have been removed.

This is the most structurally significant development in the overnight data. The flight-to-quality impulse that defined March 10's portfolio construction has not been replaced by a new defensive substitute. It has been replaced by speculative biotech and China ADRs. The system is not suggesting the macro risk has abated — breadth is still deteriorating. It is suggesting that, within the cross-section of names still showing constructive technical setups, the composition has shifted toward higher-risk, higher-potential-return names.

Whether this reflects genuine rotation capital entering speculative biotech, or whether these names are producing false-positive technical signals in a deteriorating macro environment, cannot be resolved by the signal architecture alone. The trade plan's $30$ buys with no sells and $100$ turnover from the prior session are mathematically consistent — but the underlying names carry substantially more idiosyncratic risk than the March 10 book.

The Bearish Cohort: Consistent Across Sessions

The sell-side composition shows more stability than the buy side. Centene Corporation (CNC), the managed care insurer, scores $15$ — the lowest composite in the universe — with eight sell signals. That density of sell-side confirmation across eight independent frameworks in a single name is the mirror image of DDD's seven buy signals on March 10. Eight signals firing simultaneously against a name means every technical dimension the system monitors has turned bearish.

Republic Services (RSG) scores $20$ with five sell signals. Fair Isaac Corporation (FICO) scores $23$ with five sell signals. Genpact (G), News Corp (NWS), Dolby Laboratories (DLB), and Waste Connections (WCN) all score $24$. FTI Consulting (FCN) scores $28$. CRISPR Therapeutics (CRSP) scores $27$ — the one biotech name appearing on the sell side, against the dominant biotech presence on the buy side, illustrating the degree of dispersion within the sector.

The thematic composition of the bearish cohort — healthcare insurers, waste management, fintech and data companies, media — persists from March 10. PayPal (PYPL) and Affirm (AFRM) appeared in the bottom decile on March 10; today FICO, Genpact, and FTI Consulting describe the same cluster of financial data and professional services names under distribution. These businesses share exposure to enterprise budget decisions and consumer financial conditions. The simultaneous technical deterioration across multiple names in this cluster is not coincidental.

Energy Build-Up: The Same Tension, Larger Scale

The volatility energy scan identifies $44$ symbols with energy scores above the watchlist threshold — unchanged in count from March 10. Among the top $40$ names, directional bias is $18$ upside versus $17$ downside with $5$ neutral. The near-symmetrical split is also unchanged from the prior session.

The composition within that balanced tension is consistent with the signal filter narrative. Speculative names dominate the downside energy bucket: BKKT (energy $99.62$, explosion probability $99.68$, downside bias), Ballard Power Systems (BLDP, energy $96.56$), ArQit Quantum (ARQQ, energy $95.96$), Blink Charging (BLNK, energy $94.46$). These are names with thin or negative fundamental anchors — the energy accumulation reflects compressed volatility coiling toward resolution in the direction of the underlying deterioration.

The upside energy names are structurally different. Bristol-Myers Squibb (BMY) shows energy of $94.55$ with upside bias. Academy Sports and Outdoors (ASO) shows $94.54$ with upside bias. Acacia Research (ACTG) shows $97.97$ with upside bias — the highest upside energy reading in the scan. Alexander & Baldwin (ALEX) shows $92.88$ with upside bias.

The pattern from March 10 is intact: speculative and momentum-dependent names coil toward downside energy resolution; defensive, cash-flow-anchored names coil toward upside resolution. The energy build-up data is not producing a directional signal for the broad market. It is restating the sector-rotation thesis for the second consecutive session.

The Monthly Rebalance and $100$ Turnover

The monthly rebalance for the US portfolio executes with $100$ turnover. The complete prior book — XENE, UTHR, BILI, DYN, DDD, STM, AL, KC, USIG, VCLT, ISTB — has been liquidated and replaced.

The March 10 names that scored $100$ composite — DDD, DYN, UTHR, XENE, BILI — held their positions for exactly one session. The system does not carry forward names that no longer rank at the top of the cross-section. That is the intended behavior of a systematic model with daily signal refresh. But the speed of the cohort rotation is notable. The names that triggered six and seven buy signals simultaneously on March 10 do not appear in today's scan at all.

The new book concentrates heavily in biotech and pharma: NIO, TENX, BBIO, RERE, VRTX at approximately $3.8$ allocation each; MAZE, MGTX, BIOA, ZNTL, AMRN at approximately $3.7$. Micron (MU) enters at $3.19$. Eton Pharmaceuticals (ETON), Cingulate (CING), SEI Investments (SEI), MMKT, and MEC complete the book at smaller weights.

The portfolio has no bond ETF exposure, no investment-grade duration, and no industrial names at significant weight beyond the energy infrastructure name SEI. It is a more concentrated risk-seeking book than March 10's, despite being deployed into an environment where the breadth data shows no improvement. The system is identifying a specific subset of names with constructive technical structures — it is not making a top-down judgment about the broad market's direction.

Two Competing Readings of the Same Data

The March 11 dataset supports two structurally coherent interpretations.

The first: the risk pressure easing from $19.19$ to $15.13$ is early confirmation that the breadth deterioration is losing momentum. The disappearance of bond ETFs from the signal scan reflects not that flight-to-quality is over, but that those ETFs have already repriced to reflect the defensive rotation — they are no longer statistically cheap on a technical basis. The new biotech and China ADR names are appearing because they are where residual momentum now lives, and their technical setups are genuine.

The second: the broad breadth data has not confirmed any stabilization. $34$ above MA50 is worse than $35$. The rotation from established defensive healthcare (UTHR, REGN) to speculative small-cap biotech (TENX, BIOA, MAZE, ZNTL) is not a rotation toward safety — it is a rotation toward higher-beta names within a sector that happens to have uncorrelated technical setups. The absence of bond ETFs may reflect their own technical exhaustion after the March 10 run, not an improved risk environment. NIO leading a US cross-section scan on a risk-off day is a signal worth examining carefully before treating as a regime change.

Both readings are defensible. The signal architecture is generating a pharma/biotech cohort with genuine technical confirmation. The macro context — $20$ new 20-day lows, $34$ breadth, elevated-but-easing risk pressure — has not changed in character. A systematic approach holds the positions the model identifies and adjusts when the daily signal refresh changes the ranking. The interpretation of what those positions mean about the broader market is a separate question.

What the data establishes without ambiguity is this: the US equity cross-section continues to differentiate sharply between names rather than moving uniformly, the sell-side themes persist across sessions while the buy-side themes rotate rapidly, and the energy build-up data describes a market preparing for divergent resolution — up in the defensive names, down in the speculative ones — rather than a coordinated directional move.

The cohort that led on March 10 is gone. The cohort leading on March 11 is already different from what led the previous session. In a market that refreshes its winners overnight, the question worth holding is whether the rotation speed itself is signal.